{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:15:28Z","timestamp":1783350928015,"version":"3.54.6"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"DOI":"10.1007\/s13555-025-01482-3","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T03:19:09Z","timestamp":1752808749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Biologic Sequence for the Treatment of Psoriatic Arthritis Following Nonresponse: A Narrative Review"],"prefix":"10.1007","author":[{"given":"Nicole D.","family":"Boswell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Ries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5540-8850","authenticated-orcid":false,"given":"Shikha","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"issue":"1","key":"1482_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-265.e19. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.027.","journal-title":"J Am Acad Dermatol"},{"key":"1482_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054901","author":"AB Azuaga","year":"2023","unstructured":"Azuaga AB, Ram\u00edrez J, Ca\u00f1ete JD. Psoriatic arthritis: pathogenesis and targeted therapies. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24054901.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1482_CR3","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/art.38995","volume":"67","author":"J Belasco","year":"2015","unstructured":"Belasco J, Louie JS, Gulati N, et al. Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthritis Rheumatol. 2015;67(4):934\u201344. https:\/\/doi.org\/10.1002\/art.38995.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"1482_CR4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465\u201379. https:\/\/doi.org\/10.1038\/s41584-022-00798-0.","journal-title":"Nat Rev Rheumatol"},{"key":"1482_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkab042","author":"R Cooksey","year":"2021","unstructured":"Cooksey R, Rahman MA, Kennedy J, Brophy S, Choy E. Biologic use in psoriatic arthritis and ankylosing spondylitis patients: a descriptive epidemiological study using linked, routine data in Wales, UK. Rheumatol Adv Pract. 2021. https:\/\/doi.org\/10.1093\/rap\/rkab042.","journal-title":"Rheumatol Adv Pract"},{"issue":"9894","key":"1482_CR6","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/s0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(13)60594-2.","journal-title":"Lancet"},{"issue":"6","key":"1482_CR7","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204655.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1482_CR8","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","volume":"48","author":"EG Araujo","year":"2019","unstructured":"Araujo EG, Englbrecht M, Hoepken S, et al. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum. 2019;48(4):632\u20137. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.05.011.","journal-title":"Semin Arthritis Rheum"},{"issue":"10230","key":"1482_CR9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/s0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115\u201325. https:\/\/doi.org\/10.1016\/s0140-6736(20)30265-8.","journal-title":"Lancet"},{"issue":"10230","key":"1482_CR10","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/s0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126\u201336. https:\/\/doi.org\/10.1016\/s0140-6736(20)30263-4.","journal-title":"Lancet"},{"issue":"3","key":"1482_CR11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","volume":"81","author":"LC Coates","year":"2022","unstructured":"Coates LC, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022;81(3):359\u201369. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220991.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1482_CR12","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1093\/rheumatology\/keac605","volume":"62","author":"A \u00d6st\u00f6r","year":"2023","unstructured":"\u00d6st\u00f6r A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study. Rheumatology (Oxford). 2023;62(6):2122\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keac605.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1482_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","volume":"81","author":"A \u00d6st\u00f6r","year":"2022","unstructured":"\u00d6st\u00f6r A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis. 2022;81(3):351\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221048.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1482_CR14","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1111\/ijd.16849","volume":"62","author":"AG Vaiopoulos","year":"2023","unstructured":"Vaiopoulos AG, Dalamaga M, Katsimbri P, et al. Real-world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult-to-treat areas. Int J Dermatol. 2023;62(11):1404\u201313. https:\/\/doi.org\/10.1111\/ijd.16849.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1482_CR15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40801-024-00428-z","volume":"11","author":"JA Walsh","year":"2024","unstructured":"Walsh JA, Lin I, Zhao R, et al. Comparison of real-world on-label treatment persistence in patients with psoriatic arthritis receiving guselkumab versus subcutaneous tumor necrosis factor inhibitors. Drugs Real World Outcomes. 2024;11(3):487\u201399. https:\/\/doi.org\/10.1007\/s40801-024-00428-z.","journal-title":"Drugs Real World Outcomes"},{"issue":"6","key":"1482_CR16","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/annrheumdis-2021-221640","volume":"81","author":"L Gossec","year":"2022","unstructured":"Gossec L, Siebert S, Bergmans P, et al. Persistence and effectiveness of the IL-12\/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. Ann Rheum Dis. 2022;81(6):823\u201330. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221640.","journal-title":"Ann Rheum Dis"},{"issue":"10235","key":"1482_CR17","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/s0140-6736(20)30564-x","volume":"395","author":"IB McInnes","year":"2020","unstructured":"McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020;395(10235):1496\u2013505. https:\/\/doi.org\/10.1016\/s0140-6736(20)30564-x.","journal-title":"Lancet"},{"issue":"4","key":"1482_CR18","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s40744-020-00250-3","volume":"7","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Sebba A, Ruderman EM, et al. Efficacy and safety of ixekizumab with or without methotrexate in biologic-na\u00efve patients with psoriatic arthritis: 52-week results from SPIRIT-H2H study. Rheumatol Ther. 2020;7(4):1021\u201335. https:\/\/doi.org\/10.1007\/s40744-020-00250-3.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"1482_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209709.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1482_CR20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3899\/jrheum.170429","volume":"45","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Gladman DD, Kishimoto M, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1). J Rheumatol. 2018;45(3):367\u201377. https:\/\/doi.org\/10.3899\/jrheum.170429.","journal-title":"J Rheumatol"},{"issue":"11","key":"1482_CR21","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/rheumatology\/key182","volume":"57","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Combe B, Kremer JM, et al. Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2. Rheumatology (Oxford). 2018;57(11):2001\u201311. https:\/\/doi.org\/10.1093\/rheumatology\/key182.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1482_CR22","first-page":"566","volume":"37","author":"A Kavanaugh","year":"2019","unstructured":"Kavanaugh A, Marzo-Ortega H, Vender R, et al. Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks. Clin Exp Rheumatol. 2019;37(4):566\u201374.","journal-title":"Clin Exp Rheumatol"},{"issue":"10370","key":"1482_CR23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","volume":"401","author":"JF Merola","year":"2023","unstructured":"Merola JF, Landew\u00e9 R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet. 2023;401(10370):38\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(22)02303-0.","journal-title":"Lancet"},{"issue":"7","key":"1482_CR24","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1093\/rheumatology\/kead705","volume":"63","author":"PJ Mease","year":"2024","unstructured":"Mease PJ, Gladman DD, Merola JF, et al. Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis. Rheumatology. 2024;63(7):1779\u201389. https:\/\/doi.org\/10.1093\/rheumatology\/kead705.","journal-title":"Rheumatology"},{"issue":"5","key":"1482_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamadermatol.2022.0364","volume":"158","author":"L Pina Vegas","year":"2022","unstructured":"Pina Vegas L, Penso L, Claudepierre P, Sbidian E. Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French Health Insurance Database. JAMA Dermatol. 2022;158(5):513\u201322. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0364.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1482_CR26","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1093\/rheumatology\/keaa710","volume":"60","author":"JG Letarouilly","year":"2021","unstructured":"Letarouilly JG, Flachaire B, Labadie C, et al. Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison. Rheumatology (Oxford). 2021;60(6):2773\u201382. https:\/\/doi.org\/10.1093\/rheumatology\/keaa710.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1482_CR27","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","volume":"80","author":"X Baraliakos","year":"2021","unstructured":"Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021;80(5):582\u201390. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218808.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1482_CR28","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019;71(2):258\u201370. https:\/\/doi.org\/10.1002\/art.40728.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1482_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","volume":"22","author":"K Yang","year":"2021","unstructured":"Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2021;22(2):173\u201392. https:\/\/doi.org\/10.1007\/s40257-020-00578-0.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1482_CR30","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1186\/s13063-022-06589-y","volume":"23","author":"DD Gladman","year":"2022","unstructured":"Gladman DD, Mease PJ, Bird P, et al. Efficacy and safety of guselkumab in biologic-na\u00efve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. Trials. 2022;23(1):743. https:\/\/doi.org\/10.1186\/s13063-022-06589-y.","journal-title":"Trials"},{"issue":"3","key":"1482_CR31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405\u201317. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.041.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1482_CR32","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418\u201331. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.042.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1482_CR33","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","volume":"385","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2102388.","journal-title":"N Engl J Med"},{"issue":"11","key":"1482_CR34","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1136\/ard-2023-224431","volume":"82","author":"CT Ritchlin","year":"2023","unstructured":"Ritchlin CT, Coates LC, McInnes IB, et al. Bimekizumab treatment in biologic DMARD-na\u00efve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study. Ann Rheum Dis. 2023;82(11):1404\u201314. https:\/\/doi.org\/10.1136\/ard-2023-224431.","journal-title":"Ann Rheum Dis"},{"issue":"10201","key":"1482_CR35","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/s0140-6736(19)31773-8","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(19)31773-8.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"1482_CR36","doi-asserted-by":"publisher","first-page":"150","DOI":"10.31138\/mjr.33.1.150","volume":"33","author":"CG Gialouri","year":"2022","unstructured":"Gialouri CG, Evangelatos G, Fragoulis GE. Choosing the appropriate target for the treatment of psoriatic arthritis: TNF\u03b1, IL-17, IL-23 or JAK inhibitors? Mediterr J Rheumatol. 2022;33(Suppl 1):150\u201361. https:\/\/doi.org\/10.31138\/mjr.33.1.150.","journal-title":"Mediterr J Rheumatol"},{"issue":"5","key":"1482_CR37","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s40257-024-00874-z","volume":"25","author":"ND Boswell","year":"2024","unstructured":"Boswell ND, Singla S, Gordon KB. Sequencing of targeted therapy in psoriasis: does it matter? Am J Clin Dermatol. 2024;25(5):795\u2013810. https:\/\/doi.org\/10.1007\/s40257-024-00874-z.","journal-title":"Am J Clin Dermatol"},{"issue":"10349","key":"1482_CR38","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/s0140-6736(22)01212-0","volume":"400","author":"A Deodhar","year":"2022","unstructured":"Deodhar A, Van den Bosch F, Poddubnyy D, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10349):369\u201379. https:\/\/doi.org\/10.1016\/s0140-6736(22)01212-0.","journal-title":"Lancet"},{"issue":"2","key":"1482_CR39","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/art.40759","volume":"71","author":"P Mease","year":"2019","unstructured":"Mease P. Ustekinumab fails to show efficacy in a phase III axial spondyloarthritis program: the importance of negative results. Arthritis Rheumatol. 2019;71(2):179\u201381. https:\/\/doi.org\/10.1002\/art.40759.","journal-title":"Arthritis Rheumatol"},{"key":"1482_CR40","doi-asserted-by":"publisher","first-page":"1279525","DOI":"10.3389\/fphar.2024.1279525","volume":"15","author":"J Lin","year":"2024","unstructured":"Lin J, Ren Y. Different biologics for biological-na\u00efve patients with psoriatic arthritis: a systematic review and network meta-analysis. Front Pharmacol. 2024;15:1279525. https:\/\/doi.org\/10.3389\/fphar.2024.1279525.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1482_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","volume":"47","author":"JF Merola","year":"2017","unstructured":"Merola JF, Lockshin B, Mody EA. Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum. 2017;47(1):29\u201337. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.02.001.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1482_CR42","doi-asserted-by":"publisher","first-page":"e000990","DOI":"10.1136\/rmdopen-2019-000990","volume":"5","author":"IB McInnes","year":"2019","unstructured":"McInnes IB, Chakravarty SD, Apaolaza I, Kafka S, Hsia EC, You Y, Kavanaugh A (2019) Efficacy of ustekinumab in biologic-na\u00efve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2. RMD open 5(2):e000990. https:\/\/doi.org\/10.1136\/rmdopen-2019-000990","journal-title":"RMD open"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01482-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01482-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01482-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T03:19:10Z","timestamp":1752808750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01482-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":42,"alternative-id":["1482"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01482-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The contents of this article are based on previously conducted studies and does not contain any new information from human or animal studies performed by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Nicole D. Boswell and Alexa Ries have no conflicts of interest to disclose. Kenneth B. Gordon has received honoraria for consulting and\/or received research support from Almirall, AbbVie, Eli Lilly, Janssen, UCB, Acelyrin, Amgen, Dermavant Sciences, Leo, Novartis, Pfzer, Incyte, Moon Lake, Bristol Myers Squibb, and Protagonist. Shikha Singla has received honoraria for consulting from AbbVie, UCB, and Janssen and a research grant from Prometheus Biosciences.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}